4-羟基-7-甲基-2-萘羧酸 | 24894-73-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4-羟基-7-甲基-2-萘羧酸
• 英文名称: 7-methyl-4-hydroxy-2-naphthoic acid
• 英文别名: 4-hydroxy-7-methylnaphthalene-2-carboxylic acid；1-Hydroxy-6-methyl-naphthalin-3-carbonsaeure；1-Hydroxy-6-methyl-naphthalin-carbonsaeure-(3)；2-Naphthalenecarboxylic acid, 4-hydroxy-7-methyl-
• CAS: 24894-73-3
• 化学式: C₁₂H₁₀O₃
• 分子量: 202.21
• InChiKey: GKQMUVJVSLZRDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-羟基-7-甲基-2-萘羧酸 生成 4-羟基-7-甲基-2-萘羧酸甲酯
  参考文献：
  名称：

  Jordanides,C., Justus Liebigs Annalen der Chemie, 1969, vol. 729, p. 240 - 243

  摘要：

  DOI：
• 作为产物：
  描述：

  8-bromo-4-hydroxy-7-methylnaphthalene-2-carboxylic acid 在 palladium-carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 48.0h， 以to give the title compound (0.32 g)的产率得到4-羟基-7-甲基-2-萘羧酸
  参考文献：
  名称：

  Fused-ring derivative and medical application of same

  摘要：

  本发明提供了化合物，作为预防或治疗与异常血浆尿酸水平等相关疾病的药剂。本发明涉及以下式（I）所代表的融合环衍生物，具有黄嘌呤氧化酶抑制活性，并且作为预防或治疗与血浆尿酸水平异常相关疾病的药剂、它们的前药、其盐或类似物。在式（I）中，X1和X2代表CH或N；环U代表芳基或杂环芳基；m表示从0到2的整数；n表示从0到3的整数；R1代表羟基、氨基或C1-6烷基；R2代表C1-6烷基、C1-6烷氧基C1-6烷基或类似物。

  公开号：

  US08263622B2

文献信息

• Synthesis of 6-deoxymollugins and their inhibitory activities on tyrosinase
  作者：Jing Lu Liang、Umair Javed、Seung Ho Lee、Jae Gyu Park、Yurngdong Jahng

  DOI：10.1007/s12272-013-0240-1

  日期：2014.7

  A series of 6-deoxymollugins were prepared five steps from benzaldehyde and its derivatives via phenylboronic acid-catalyzed chromenylation as a key step. Their inhibitory activities against tyrosinase from mushroom were evaluated to show that the parent, methyl 2,2-dimethyl-2H-benzo[h]chromene-5-carboxylate (9a) showed best and promising inhibitory activity at IC50 = 18.3 μM.

  以苯甲醛及其衍生物为原料，通过苯硼酸催化的铬化反应为关键步骤，分五个步骤制备了一系列6-脱氧毛蕊花素。结果表明，母体 2,2-二甲基-2H-苯并[h]色烯-5-羧酸甲酯（9a）的抑制活性最好，IC50 = 18.3 μM。
• Substituted napthopyrans
  申请人：Transition Optical, Inc.

  公开号：US06340766B1

  公开（公告）日：2002-01-22

  Described are novel reversible photochromic naphthopyran compounds, examples of which are compounds having a cycloalkyl ester substituent at the number 5 carbon atom and optionally certain substituents at the number 6 carbon atom of the naphtho portion of the naphthopyran and certain substituents at the 2-position of the pyran ring. Substituents may also be present at the number 7, 8, 9 or 10 carbon atoms of the naphtho portion of the naphthopyran. These compounds may be represented by the following graphic formulae: Also described are various substrates, e.g., paper, glass, organic polymeric materials, etc., that contain or that are coated with such compounds. Optically clear articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., certain other naphthopyrans, indenonaphthopyrans, benzopyrans, oxazine-type compounds, etc., are also described.

  本文介绍了一种新型可逆光致变色萘并吡喃化合物，其中一些化合物在萘环部分的第5个碳原子处具有环烷酯基取代物，还可以在萘环部分的第6个碳原子处和吡喃环的2位处具有某些取代基。此外，萘并吡喃的第7、8、9或10个碳原子处也可能存在取代基。这些化合物可以用以下图式表示：本文还介绍了各种基质，例如纸张、玻璃、有机聚合材料等，这些基质包含或涂覆有这些化合物。此外，还介绍了光学透明的物品，例如眼镜镜片或其他塑料透明物品，它们包含新型萘并吡喃化合物或与互补光致变色化合物（例如其他萘并吡喃、茚诺萘并吡喃、苯并吡喃、噁唑型化合物等）的组合。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Quinoline-carboxamide derivatives as P2Y12 antagonists
  申请人：Nazare Marc

  公开号：US08669266B2

  公开（公告）日：2014-03-11

  The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述权利要求中指定的含义。公式I的化合物是有价值的药理活性化合物。它们在血小板上表现出强烈的抗聚集作用，因此具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常可以应用于存在不希望的血小板ADP受体P2Y12激活或需要抑制血小板ADP受体P2Y12的治疗或预防的情况。此外，本发明还涉及公式I的化合物的制备方法，它们的使用，特别是作为药物的活性成分，以及包含它们的药物制剂。
• Fluorescent dye compounds, conjugates and uses thereof
  申请人：Life Technologies Corporation

  公开号：EP2371927A1

  公开（公告）日：2011-10-05

  The present teachings generally relate to fluorescent dyes, linkable forms of fluorescent dyes, energy transfer dyes, reagents labeled with fluorescent dyes and uses thereof.

  本教导一般涉及荧光染料、荧光染料的可连接形式、能量转移染料、用荧光染料标记的试剂及其用途。